top of page

Ambulero will file an IND for our lead gene therapy product AMB-301 by early 2023.


Initial start-up funding and business support has been provided by Ventac Holding, LLC. Drs. Omaida Velazquez’s and Zhao-Jun Liu's research has been supported by the NIH including funding from the prestigious Vascular Interventions/Innovations and Therapeutic Advances (VITA) program. Dr. Velazquez’ work has also been supported by the The Wallace H. Coulter Center for Translational Research at the University of Miami.

bottom of page